NEW YORK — Exagen on Wednesday reported a 6 percent year-over-year increase in fourth quarter revenues as the company benefitted from its copromotion alliance with Janssen Biotech.
For the three-month period ended Dec. 31, 2019, Exagen's revenues rose to $10.2 million from $9.6 million in the same period a year earlier. Revenues from its autoimmune disease testing portfolio, including its flagship Avise CTD lupus assessment test, were flat year over year at $9.6 million as higher testing volume was offset by lower average selling prices.